Introduction Tirzepatide, a recently approved glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulin tropic polypeptide (GIP) dual agonist for the treatment of type 2 diabetes, has generated considerable excitement because of its robust efficacy in blood sugar reduction with substantial weight loss. One of the areas that are interesting to researchers as they investigate its […]